EA201492004A1 - Органические композиции для лечения kras-ассоциированных заболеваний - Google Patents
Органические композиции для лечения kras-ассоциированных заболеванийInfo
- Publication number
- EA201492004A1 EA201492004A1 EA201492004A EA201492004A EA201492004A1 EA 201492004 A1 EA201492004 A1 EA 201492004A1 EA 201492004 A EA201492004 A EA 201492004A EA 201492004 A EA201492004 A EA 201492004A EA 201492004 A1 EA201492004 A1 EA 201492004A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- kras
- lung
- syndrome
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641588P | 2012-05-02 | 2012-05-02 | |
| PCT/US2013/038847 WO2013166004A2 (en) | 2012-05-02 | 2013-04-30 | Organic compositions to treat kras-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201492004A1 true EA201492004A1 (ru) | 2015-08-31 |
Family
ID=48366565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201492004A EA201492004A1 (ru) | 2012-05-02 | 2013-04-30 | Органические композиции для лечения kras-ассоциированных заболеваний |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150238515A1 (https=) |
| EP (3) | EP2844757A2 (https=) |
| JP (1) | JP2015517466A (https=) |
| KR (1) | KR20150004414A (https=) |
| CN (2) | CN109481455A (https=) |
| AU (5) | AU2013256471A1 (https=) |
| BR (1) | BR112014027337A2 (https=) |
| CA (2) | CA2872304C (https=) |
| EA (1) | EA201492004A1 (https=) |
| HK (1) | HK1206387A1 (https=) |
| MX (1) | MX2014013367A (https=) |
| WO (1) | WO2013166004A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620525A (zh) * | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
| KR102589295B1 (ko) | 2014-05-14 | 2023-10-13 | 타르그이뮨 테라퓨틱스 아게 | 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터 |
| US11180759B2 (en) * | 2016-01-19 | 2021-11-23 | The University Of North Carolina At Chapel Hill | Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| EP3436585B1 (en) * | 2016-04-01 | 2022-07-20 | Avidity Biosciences, Inc. | Kras nucleic acids and uses thereof |
| KR102543645B1 (ko) * | 2016-07-20 | 2023-06-16 | 주식회사 지씨지놈 | 유전성 발달장애 진단용 조성물 및 이의 용도 |
| AU2018378812B2 (en) | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| EP3993806A4 (en) * | 2019-06-05 | 2023-09-13 | Southern Research Institute | Thiarabine- and thiarabine prodrug-based treatments |
| EP4058152A4 (en) * | 2019-11-14 | 2024-05-08 | The Board of Regents of the University of Oklahoma | PROSTATE CANCER TREATMENTS USING OLIGONUCLEOTIDES INTERFERENCE |
| WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| JP7839554B2 (ja) * | 2020-04-07 | 2026-04-02 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 |
| KR20240051272A (ko) * | 2021-09-02 | 2024-04-19 | 몰레큘라 악시옴, 엘엘씨 | Kras 발현을 조절하기 위한 조성물 및 방법 |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| EP4652279A2 (en) * | 2023-01-18 | 2025-11-26 | Molecular Axiom, LLC | Compositions for modulating kras expression and uses thereof |
| AU2024225428A1 (en) * | 2023-02-22 | 2025-08-28 | Altamira Therapeutics Ag | Compositions and methods for kras inhibition for the treatment of disease |
| WO2026026715A1 (zh) * | 2024-07-31 | 2026-02-05 | 前沿生物药业(南京)股份有限公司 | 一种用于抑制KRAS基因表达的siRNA及其修饰物与应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| EP1399189A1 (en) | 2001-06-11 | 2004-03-24 | Universite De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| JP5170934B2 (ja) | 2001-08-16 | 2013-03-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用 |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| US20050008617A1 (en) | 2002-09-28 | 2005-01-13 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering RNA and short hairpin RNA |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| EP1585756B1 (en) | 2002-11-26 | 2010-04-21 | University of Massachusetts | Delivery of sirnas |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| EP1660657A1 (en) | 2003-08-28 | 2006-05-31 | Novartis AG | Interfering rna duplex having blunt-ends and 3'-modifications |
| WO2005044981A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| EP1714970A1 (en) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| WO2007107162A2 (en) | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| AU2007299705B2 (en) * | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| EP2121925A2 (en) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
| KR101629017B1 (ko) | 2007-05-22 | 2016-06-10 | 아크투루스 쎄라퓨틱스, 인크. | 히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체 |
| JP2010538678A (ja) * | 2007-09-18 | 2010-12-16 | イントラドイグム コーポレーション | Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法 |
| WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| ES2535419T3 (es) | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Silenciamiento de expresión de quinasa tipo polo usando ARN interferente |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| US20110218334A1 (en) * | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| CN103555722B (zh) * | 2009-04-03 | 2016-08-31 | 戴瑟纳制药公司 | 利用不对称双链rna特异性抑制kras的方法和组合物 |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2011110671A2 (en) * | 2010-03-12 | 2011-09-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pharmaceutical composition for the treatment of chlamydial infection |
-
2013
- 2013-04-30 EA EA201492004A patent/EA201492004A1/ru unknown
- 2013-04-30 CN CN201811456141.9A patent/CN109481455A/zh active Pending
- 2013-04-30 EP EP13721578.6A patent/EP2844757A2/en not_active Withdrawn
- 2013-04-30 BR BR112014027337A patent/BR112014027337A2/pt not_active IP Right Cessation
- 2013-04-30 CA CA2872304A patent/CA2872304C/en active Active
- 2013-04-30 MX MX2014013367A patent/MX2014013367A/es unknown
- 2013-04-30 KR KR1020147033421A patent/KR20150004414A/ko not_active Withdrawn
- 2013-04-30 AU AU2013256471A patent/AU2013256471A1/en not_active Abandoned
- 2013-04-30 JP JP2015510380A patent/JP2015517466A/ja active Pending
- 2013-04-30 EP EP20178501.1A patent/EP3736333A1/en active Pending
- 2013-04-30 EP EP17187348.2A patent/EP3272868A1/en not_active Ceased
- 2013-04-30 WO PCT/US2013/038847 patent/WO2013166004A2/en not_active Ceased
- 2013-04-30 CN CN201380035099.2A patent/CN104583406A/zh active Pending
- 2013-04-30 US US14/397,815 patent/US20150238515A1/en not_active Abandoned
- 2013-04-30 CA CA3173610A patent/CA3173610A1/en active Pending
- 2013-04-30 HK HK15106884.9A patent/HK1206387A1/xx unknown
-
2016
- 2016-07-11 AU AU2016204832A patent/AU2016204832A1/en not_active Abandoned
- 2016-09-07 US US15/258,042 patent/US20180153919A1/en not_active Abandoned
-
2017
- 2017-11-14 AU AU2017261481A patent/AU2017261481A1/en not_active Abandoned
-
2020
- 2020-01-14 AU AU2020200247A patent/AU2020200247A1/en not_active Abandoned
-
2022
- 2022-05-04 AU AU2022202991A patent/AU2022202991A1/en not_active Abandoned
-
2024
- 2024-11-21 US US18/954,771 patent/US20260069625A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020200247A1 (en) | 2020-02-06 |
| HK1206387A1 (en) | 2016-01-08 |
| AU2013256471A1 (en) | 2014-11-13 |
| JP2015517466A (ja) | 2015-06-22 |
| WO2013166004A2 (en) | 2013-11-07 |
| MX2014013367A (es) | 2014-12-08 |
| BR112014027337A2 (pt) | 2017-07-18 |
| AU2017261481A1 (en) | 2017-11-30 |
| WO2013166004A3 (en) | 2014-01-03 |
| AU2022202991A1 (en) | 2022-05-26 |
| CA2872304A1 (en) | 2013-11-07 |
| CN104583406A (zh) | 2015-04-29 |
| EP2844757A2 (en) | 2015-03-11 |
| CN109481455A (zh) | 2019-03-19 |
| AU2016204832A1 (en) | 2016-07-28 |
| US20180153919A1 (en) | 2018-06-07 |
| US20150238515A1 (en) | 2015-08-27 |
| US20260069625A1 (en) | 2026-03-12 |
| EP3272868A1 (en) | 2018-01-24 |
| CA3173610A1 (en) | 2013-11-07 |
| KR20150004414A (ko) | 2015-01-12 |
| CA2872304C (en) | 2022-12-06 |
| EP3736333A1 (en) | 2020-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| NZ731797A (en) | Dna-pk inhibitors | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| UA111604C2 (uk) | ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ | |
| NZ705910A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| EA201792169A1 (ru) | 5'-замещенные нуклеозидные соединения | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| NZ718826A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| SV2011003812A (es) | Derivados de piridazina como inhibidores de smo. | |
| MX2011012584A (es) | Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación. | |
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| EA201690080A1 (ru) | Применение молекул, ингибирующих семафорин-4d, в комбинации с иммуномодулирующей терапией для ингибирования роста и метастазирования опухолей | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| MX389105B (es) | Inhibidor de quinasas reordenadas durante la transfeccion (ret). | |
| PH12012501836A1 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| NZ626942A (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| CL2015001818A1 (es) | Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras. | |
| MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
| IN2014DN09228A (https=) | ||
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| CL2011001152A1 (es) | Compuesto cristalino 6-((s)-1-(6-(1-metil-1h-pirazol-4-il)-[1,2,4]triazolo[3,4-b][1,3,4]tiadiazol-3-il)etil)quinolina, inhibidor de la proteina kinasa c-met; composicion farmaceutica; y metodo para tratar o disminuir la gravedad de un trastorno proliferativo tal como cancer metastasico de colon, mama y hepatico, entre otros. | |
| CL2014002181A1 (es) | Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. | |
| EA201301265A1 (ru) | Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли | |
| PH12015502757A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |